Taiho Oncology and Servier present Lonsurf data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Taiho Oncology Inc. and Servier announced clinical data with Lonsurf (trifluridine and tipiracil, TAS-102) in previously treated patients with metastatic gastric cancer, metastatic gastroesophageal junction adenocarcinoma, and metastatic colorectal cancer were presented at the 2019 ASCO Annual Meeting.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login